Sorrento Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sorrento Therapeutics, Inc.
Glenmark’s US-based innovation arm Ichnos delivers first licensing deal for IL-1RAP antagonist, while early data for a bispecific antibody demonstates promising activity in multiple in vitro and in vivo tumor models relative to daratumumab and magrolimab.
Multiple non-vaccine options for COVID-19 continue to progress, with promising new clinical results for Sorrento's small molecule drug and a supplementary approval in Japan for Chugai's antibody combo. Meanwhile, China's CRDC has in-licensed technology for Ligand to apply to an oral antiviral it is developing. Meanwhile, SK Biosciences' novel nanoparticle vaccine is positive in early trials.
$47.5m partnership between the foundation and Broad researchers will mine genetic data for insights into disease mechanisms. MD Anderson, Nuvectis each unveil multiple new tie-ups.
The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.
- Medical Devices
- Specialty Pharmaceuticals
- Site Specific
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Large Molecule
- Other Names / Subsidiaries
- ADNAB, Inc.
- Levena (Suzhou) Biopharma Co., Ltd
- SCILEX Pharmaceuticals, Inc.
- Scilex Holding Company
- Scintilla Pharmaceuticals, Inc.
- Semnur Pharmaceuticals, Inc.
- Sherrington Pharmaceuticals
- SmartPharm Therapeutics, Inc.
- TNK Therapeutics, Inc.
- Virttu Biologics Limited